7:15 AM ET
8-K
Business Update
uniQure Business Update
uniQure announced that the FDA has accepted its Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington’s disease, for review under the Accelerated Approval pathway. The FDA granted the application Priority Review with a PDUFA target action date of May 1, 2027, and is tentatively planning an Advisory Committee meeting to discuss the application.
- Counterparty
- FDA